It is demonstrated that the downregulation of TFPI-2 expression was significantly correlated with the promoter hypermethylation in some cancer lesions and cell lines, such as nasopharyngeal carcinoma [10], hepatocellular carcinoma [11], lung cancer [22] and breast cancer [23]. The gene discussed is TFPI2; the disease is breast carcinoma.